Supplemental material

Appendix S1: MEDLINE (Ovid) search strategy

1. exp *Pneumonia/
2. ((respiratory adj3 infection*) or pneumonia or pneumonias or lung-inflammation* or lobitis or nonspecificinflammatory-lung-disease* or peripneumonia or pleuropneumonia or pleuropneumonitis or pneumonic-lung* or pneumonic-pleurisy or pneumonic-pleuritis or pneumonitides or pneumonitis or pulmonal-inflammation* or pulmonary-inflammation* or pulmonic-inflammation* or bronchiolitis).tw,kf.
3. *Pneumococcal Infections/
4. 1 or 2 or 3 5. exp Comorbidity/
6. co.fs.
7. hospitalization/ or patient admission/
8. adolescent, hospitalized/ or child, hospitalized/ or inpatients/
9. "Severity of Illness Index"/
10. (inpatient* or admission* or hospital* or severe or comorbidit* or co-morbidit* or multi-morbidit* or complication*).tw,kf.
11. 5 or 6 or 7 or 8 or 9 or 10
12. exp *Tuberculosis/
13. *Mycobacterium tuberculosis/
14. (Tuberculosis or tuberculous-infection* or tuberculous-lesion*).tw,kf. 15. 12 or 13 or 14
16. ep.fs.
17. incidence/ or prevalence/ or Prospective Studies/
18. *risk/ or exp *risk assessment/ or *risk factors/
19. (burden or risk or risks or determinant* or predict* or prospective* or incidence or prevalence).tw,kf.
20. exp "Sensitivity and Specificity"/
21. "cost of illness"/
22. 16 or 17 or 18 or 19 or 20 or 21
23. (infan* or toddler* or pre-schooler* or preschooler* or kinder or kinders or kindergarten* or kinder-aged or boy or boys or girl or girls or child or children or childhood or pediatric* or paediatric* or school-age* or schoolage* or schoolchild* or schoolgirl* or schoolboy* or adolescen* or youth or youths or teen or teens or teenage*).af.
24. (Xpert-MTB-RIF or Xpert-MTB-RIF).tw,kf.
25. (x-ray* or xray* or imaging or radiolog* or cxr or radiogra*).tw,kf,hw.
26. (mantoux or tb-test* or skin-test* or blood or serolog* or sputum or stool or gastric-aspirate* or tuberculintest* or urine or lung or culture* or specimen* or PCR or polymerase-chain-reaction* or pleural-fluid* or NP-OP or swab* or nasopharyngeal-and-oro-pharyngeal or naso-pharyngeal-and-oro-pharyngeal or nasopharyngeloaloropharyngeal or naso-pharyngeal-oro-pharyngeal).tw,kf,hw.
27. Molecular Diagnostic Techniques/ 28. Tuberculin Test/
29. ip.fs.
30. (clinical-presentation* or clinical-feature* or clinical-sign* or clinical-symptom* or clinical-syndrome*).tw,kf.
31. (diagnos* or detection or investigation*).tw,kf.
32. early diagnosis/ or delayed diagnosis/
33. 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32
34. 4 and 11 and 15 and 22 and 23 and 33
35. limit 34 to (english language and yr="1990 -Current")
Appendix S2: Prevalence of bacteriologically confirmed TB (BCTB) in studies of children with pneumonia

![Graph showing the prevalence of bacteriologically confirmed TB (BCTB) in pneumonia cases from 1990 to 2020. The graph displays data points for each year, with a horizontal line indicating the range from 0% to 16%. The data shows a variation in prevalence over the years, with some years having a higher prevalence compared to others.](image-url)
### Appendix S3: EPHPP Quality Assessment Tool for Quantitative Studies, assessed at outcome level

| Study        | Selection Bias | Study design | Confounders | Blinding | Data collection methods | Withdrawals and dropouts | GLOBAL RATING |
|--------------|----------------|--------------|-------------|----------|-------------------------|---------------------------|-----------------|
| Adegbola 1994| Weak           | Moderate     | Moderate    | Moderate | Weak-Moderate           | Strong                    | Moderate        |
| Bolursaz 2017| Weak           | Moderate     | Weak        | Weak     | Moderate                | Moderate                  | Weak            |
| Chintu 2002  | Weak           | Moderate     | Moderate    | Strong   | Moderate                | Moderate                  | Moderate        |
| Chisti 2015  | Moderate       | Moderate-strong | Moderate   | Weak     | Moderate                | Strong                    | Moderate        |
| Graham 2011  | Moderate       | Moderate     | Weak        | Weak     | Weak                    | Strong                    | Weak            |
| Hammitt 2012 | Moderate       | Moderate     | Weak        | Moderate | Moderate                | Moderate                  | Moderate        |
| Madhi 2000   | Weak           | Moderate     | Weak        | Moderate | Moderate                | Strong                    | Weak            |
| McNally 2007 | Moderate       | Strong       | Moderate    | Moderate | Strong                  | Strong                    | Strong          |
| Moore 2010   | Weak           | Moderate     | Moderate    | Moderate | Weak                    | Strong                    | Weak            |
| Moore 2017   | Moderate       | Moderate     | Moderate    | Moderate | Moderate                | Moderate                  | Moderate        |
| Nantongo 2013| Moderate       | Strong       | Moderate    | Moderate | Moderate                | Strong                    | Strong          |
| O'Brien 2019 | Moderate       | Moderate     | Strong      | Strong   | Moderate                | Strong                    | Strong          |
| Rennert 2002 | Weak           | Moderate     | Moderate    | Moderate | Strong                  | Moderate                  | Moderate        |
| Uriyo 2006   | Moderate       | Moderate     | Weak        | Moderate | Weak                    | Moderate                  | Weak            |
| Zar 2001     | Moderate       | Moderate     | Moderate    | Moderate | Strong                  | Strong                    | Strong          |